CN101346144B - 类固醇化合物衍生物在制备药物中的用途 - Google Patents

类固醇化合物衍生物在制备药物中的用途 Download PDF

Info

Publication number
CN101346144B
CN101346144B CN2006800486827A CN200680048682A CN101346144B CN 101346144 B CN101346144 B CN 101346144B CN 2006800486827 A CN2006800486827 A CN 2006800486827A CN 200680048682 A CN200680048682 A CN 200680048682A CN 101346144 B CN101346144 B CN 101346144B
Authority
CN
China
Prior art keywords
pain
galanin
androstene
dione
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800486827A
Other languages
English (en)
Chinese (zh)
Other versions
CN101346144A (zh
Inventor
E·武尔费特
J·R·默里
D·温尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunter Fleming Ltd
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Publication of CN101346144A publication Critical patent/CN101346144A/zh
Application granted granted Critical
Publication of CN101346144B publication Critical patent/CN101346144B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN2006800486827A 2005-11-18 2006-11-17 类固醇化合物衍生物在制备药物中的用途 Expired - Fee Related CN101346144B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0523550.2 2005-11-18
GBGB0523550.2A GB0523550D0 (en) 2005-11-18 2005-11-18 Therapeutic uses of steroidal compounds
PCT/GB2006/004305 WO2007057691A2 (en) 2005-11-18 2006-11-17 Therapeutic uses of steroidal compounds

Publications (2)

Publication Number Publication Date
CN101346144A CN101346144A (zh) 2009-01-14
CN101346144B true CN101346144B (zh) 2011-07-20

Family

ID=35580318

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800486827A Expired - Fee Related CN101346144B (zh) 2005-11-18 2006-11-17 类固醇化合物衍生物在制备药物中的用途

Country Status (16)

Country Link
US (1) US8846652B2 (https=)
EP (1) EP1948192A2 (https=)
JP (1) JP5395437B2 (https=)
KR (1) KR101314694B1 (https=)
CN (1) CN101346144B (https=)
AU (1) AU2006314226B2 (https=)
CA (1) CA2630441C (https=)
GB (1) GB0523550D0 (https=)
IL (1) IL191457A (https=)
MX (1) MX2008006440A (https=)
NO (1) NO20082741L (https=)
NZ (1) NZ568560A (https=)
RU (1) RU2427375C2 (https=)
TW (1) TWI386211B (https=)
WO (1) WO2007057691A2 (https=)
ZA (1) ZA200804266B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
CN108434090A (zh) * 2017-02-14 2018-08-24 高药品股份有限公司 以生理脂肪为基剂的类固醇药膏
RU2745868C9 (ru) * 2020-05-28 2021-04-08 Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва» Способ ускорения регенерационных процессов в поврежденных периферических нервах

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012997A1 (en) 1991-01-16 1992-08-06 The General Hospital Corporation Human galanin
WO1992015015A1 (en) 1991-02-25 1992-09-03 Zymogenetic, Inc. Methods for detecting galanin antagonists
DE69225706T2 (de) 1991-03-06 1998-11-26 Garvan Institute Of Medical Research, Darlinghurst, Neu Sued Wales/New South Wales Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
SE9101472D0 (sv) 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
JPH06172387A (ja) 1992-12-11 1994-06-21 Aibaitsu Kk 合成ペプチド誘導体
EP0698612B1 (en) * 1993-05-18 2001-07-25 Ltt Institute Co., Ltd. Osteogenesis promoter and osteoporosis remedy
JPH09151197A (ja) * 1995-11-29 1997-06-10 L T T Kenkyusho:Kk 自己免疫疾患治療薬
DE69739760D1 (de) 1996-07-24 2010-03-25 Neurotargets Ltd Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen
JP2000169374A (ja) * 1998-12-03 2000-06-20 Ltt Kenkyusho:Kk Ｉｇｆ増強剤
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
GB0105772D0 (en) * 2001-03-08 2001-04-25 Sterix Ltd Use
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
WO2002096934A1 (en) 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands
DK1406606T3 (da) 2001-07-16 2007-03-05 Ortho Mcneil Pharm Inc Carbamatforbindelser til forebyggelse eller behandling af neuropatisk smerte og smerte forbundet med klynge- og migrænehovedpine
JP2004538305A (ja) 2001-07-31 2004-12-24 ファルマシア・アンド・アップジョン・カンパニー ３−ヘテロシクリル−及び３−シクロアルキル−３−アリールオキシプロパンアミンによる慢性疼痛の治療
WO2003011272A1 (en) 2001-07-31 2003-02-13 Pharmacia & Upjohn Company Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
ATE332688T1 (de) 2001-10-16 2006-08-15 Endo Pharmaceuticals Inc Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
GB0403509D0 (en) 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
JP5449775B2 (ja) * 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
WO2008065408A2 (en) 2006-11-30 2008-06-05 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways

Also Published As

Publication number Publication date
US8846652B2 (en) 2014-09-30
MX2008006440A (es) 2008-12-01
RU2008124834A (ru) 2009-12-27
JP5395437B2 (ja) 2014-01-22
WO2007057691A2 (en) 2007-05-24
TW200730180A (en) 2007-08-16
NZ568560A (en) 2010-11-26
CN101346144A (zh) 2009-01-14
IL191457A (en) 2013-10-31
AU2006314226A1 (en) 2007-05-24
WO2007057691A3 (en) 2007-08-02
CA2630441C (en) 2013-10-29
US20090227551A1 (en) 2009-09-10
ZA200804266B (en) 2009-01-28
CA2630441A1 (en) 2007-05-24
GB0523550D0 (en) 2005-12-28
JP2009515939A (ja) 2009-04-16
TWI386211B (zh) 2013-02-21
IL191457A0 (en) 2009-08-03
KR101314694B1 (ko) 2013-10-07
NO20082741L (no) 2008-07-23
KR20080073755A (ko) 2008-08-11
RU2427375C2 (ru) 2011-08-27
EP1948192A2 (en) 2008-07-30
AU2006314226B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
US20160136231A1 (en) Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
KR20090059126A (ko) 암을 치료하기 위한 방법 및 조성물
AU2005322611A1 (en) Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of Alzheimer's disease
AU2003250892B2 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
Wang et al. Human breast milk-derived exosomes protect against intestinal ischemia and reperfusion injury in neonatal rats
US20240285626A1 (en) Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy
KR20050057673A (ko) Ｊｎｋ 억제제를 이용한 통증의 치료
AU2013271841B2 (en) Method of prevention of neurological diseases
US20110195898A1 (en) Treatment of alzheimer's disease and mild cognitive impairment using gnrh-i analogs and one or more of acetylcholinesterase inhibitors and nmda receptor antagonists
RU2346690C2 (ru) Применение прегнандионов или прегнандиолов в качестве невропатических анальгетических агентов
CN101346144B (zh) 类固醇化合物衍生物在制备药物中的用途
JP4942905B2 (ja) 神経保護活性を有する７−ヒドロキシエピアンドロステロン
JP2009515939A5 (https=)
JP7002756B2 (ja) 局所と局部の麻酔と鎮痛
WO2007123234A1 (ja) 抗てんかん作用増強剤
EP1490069B1 (en) Alpha aed and beta aed regulation of nuclear transcription, gene regulation, and/or gene expression
US20060009432A1 (en) Use of neurosteroids to treat neuropathic pain
WO2023192935A1 (en) Methods and compositions for the treatment for inflammation and fibrosis in retinal neovascular diseases
JP3713271B2 (ja) ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用
JP3713271B6 (ja) ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用
JP2016509590A (ja) 加齢に伴う障害の治療のための組換え７型コラーゲンの投与
HK40013781A (en) Use of thyroid beta-agonists
US20050025743A1 (en) Method of preventing adhesions wtih ifn-upsilon
WO2015065136A1 (ko) 마시티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물
WO2015065135A1 (ko) 다사티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110720

Termination date: 20161117

CF01 Termination of patent right due to non-payment of annual fee